Although still recruiting, the first patient was randomized to receive NBI-1070770 for major depressive disorder in a phase 2 trial assessing efficacy, safety, and tolerability.
VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis
Vedanta’s pipeline also includes VE303, its Phase 3 ready therapeutic.